Patents Assigned to University of Parma
-
Publication number: 20220096433Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: ApplicationFiled: December 13, 2021Publication date: March 31, 2022Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie de MontpellierInventors: Gérard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
-
Patent number: 11213508Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: GrantFiled: January 24, 2020Date of Patent: January 4, 2022Assignees: Universite de Montpellier, University de Parma, Ecole Nationale Supérieure de Chimie de MontpellierInventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
-
Patent number: 10827259Abstract: The disclosure relates to a microphone assembly (100) for acquiring a plurality of audio signals, wherein the microphone assembly (100) has a reconfigurable geometry so that the microphone assembly (100) may be configured to be embedded in or attached to a body. The microphone assembly (100) comprises: a plurality of digital microphones (101a-h) configured to convert the sound signal impinging on each digital microphone into a corresponding digital electrical signal, a digital signal processing unit (102) comprising a serial digital communication interface (102a) and a processor (102b), and a connecting and mounting structure configured to provide a flexible electrical connection and a flexible mechanical arrangement for the plurality of digital microphones (101a-h).Type: GrantFiled: August 23, 2019Date of Patent: November 3, 2020Assignees: Huawei Technologies Co., Ltd., University of ParmaInventors: Simone Fontana, Angelo Farina
-
Patent number: 10743126Abstract: The present disclosure relates to a method and to an apparatus, both arranged for controlling acoustic signals to be recorded or reproduced by an electro-acoustical sound system. An initial digital filter is determined by solving an inverse problem, wherein the initial digital filter is configured to control acoustic signals to be recorded and/or reproduced by the electro-acoustical sound system; a frequency-dependent articulation parameter is determined by executing a time spectral psychoacoustic automatic audio quality test on the initial digital filter; a frequency-dependent regularization parameter, used for determining the initial digital filter, is tuned by use of the frequency-dependent articulation parameter; and, by use of the tuned frequency-dependent regularization parameter, a digital filter configured to control acoustic signals to be recorded or reproduced by the electro-acoustical sound system is determined.Type: GrantFiled: April 18, 2019Date of Patent: August 11, 2020Assignees: Huawei Technologies Co., Ltd., University of ParmaInventors: Simone Fontana, Angelo Farina
-
Publication number: 20200155504Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de ChimieInventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
-
Patent number: 10583114Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: GrantFiled: October 15, 2014Date of Patent: March 10, 2020Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie, Centre National de la Recherche Scientifique, Universite de MontpellierInventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
-
Publication number: 20160279097Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: ApplicationFiled: October 15, 2014Publication date: September 29, 2016Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de ChimieInventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry